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Introduction: Angiogenesis is an important factor in the development of osteoarthritis (OA). We investigated the
efficacy of bevacizumab, an antibody against vascular endothelial growth factor and an inhibitor of angiogenesis, in
the treatment of OA using a rabbit model of anterior cruciate ligament transection.
Methods: First, we evaluated the response of gene expression and histology of the normal joint to bevacizumab
treatment. Next, in a rabbit model of OA induced by anterior cruciate ligament transection, we used macroscopic
and histological evaluations and real-time polymerase chain reaction (PCR) to examine the responses to intravenous
(systemic) administration of bevacizumab (OAB IV group). We also investigated the efficacy of intra-articular (local)
administration of bevacizumab in OA-induced rabbits (OAB IA group).
Results: Histologically, bevacizumab had no negative effect in normal joints. Bevacizumab did not increase the
expression of genes for catabolic factors in the synovium, subchondral bone, or articular cartilage, but it increased
the expression of collagen type 2 in the articular cartilage. Macroscopically and histologically, the OAB IV group
exhibited a reduction in articular cartilage degeneration and less osteophyte formation and synovitis compared
with the control group (no bevacizumab; OA group). Real-time PCR showed significantly lower expression of
catabolic factors in the synovium in the OAB IV group compared with the OA group. In articular cartilage,
expression levels of aggrecan, collagen type 2, and chondromodulin-1 were higher in the OAB IV group than in the
OA group. Histological evaluation and assessment of pain behaviour showed a superior effect in the OAB IA group
compared with the OAB IV group 12 weeks after administration of bevacizumab, even though the total dosage
given to the OAB IA group was half that received by the OAB IV group.
Conclusions: Considering the dosage and potential adverse effects of bevacizumab, the local administration of
bevacizumab is a more advantageous approach than systemic administration. Our results suggest that intra-articular
bevacizumab may offer a new therapeutic approach for patients with post-traumatic OA.Introduction
Osteoarthritis (OA), the most common joint disease, is
often given less attention than other diseases, such as can-
cer, because it is not a disorder directly associated with
the sustainability of life. However, OA leads to severe joint
dysfunction and pain, and a decline in the patient’s quality
of life with an associated decrease in the ability to perform
activities of daily life. Patients with early to mid-stage OA
are given pharmacological treatment for pain relief, al-
though the long-term benefits have not been shown con-
vincingly. Patients with advanced OA are indicated for
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stated.Articular cartilage is an avascular tissue comprising a
sparse cell population with low mitotic activity, and its
capacity for self-repair is limited. Therefore, mature ar-
ticular cartilage shows limited capacity for regeneration
after degeneration or injury. For this reason, various treat-
ments have been developed with the aim of restoring tis-
sue quality via regenerative methods. Techniques such as
microfracture [1], mosaicplasty [2], cell transplantation
[3,4], and the implantation of tissue-engineered cartilage
with [5-7] or without [8-10] various scaffolding materials
have received increasing attention. However, the restor-
able areas are limited and tend to be replaced with bone
or fibrocartilage tissue.
Previously, we investigated the use of an osteochondral
defect model to explore methods to repair cartilage defecttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Nagai et al. Arthritis Research & Therapy 2014, 16:427 Page 2 of 12
http://arthritis-research.com/content/16/5/427sites. This was first accomplished by developing a three-
dimensional, scaffold-free, tissue-engineered cartilage [9]
that was transplanted into osteochondral defects to initiate
cartilage differentiation [10]. This method achieved good
restorative effects in the long term, allowing us to confirm
that articular cartilage repair can be achieved during the
early stage of transplantation [10]. We noted that repara-
tive cells from marrow had acquired anti-angiogenic prop-
erties, and we hypothesized that better cartilage repair
might be achieved by inhibiting the bioactivity of vascular
endothelial growth factor (VEGF) in osteochondral defects.
We later reported that intravenous administration of an
antibody against VEGF contributed to articular cartilage
repair in an osteochondral defect model [11].
In OA, new blood vessels from the subchondral bone
breach the tidemark into cartilage [12], and it is thought
that these blood vessels contribute to articular cartilage os-
sification [13] and lead to osteophyte formation around the
cartilage [14]. Angiogenesis and inflammation are closely
integrated processes in the pathogenesis of OA, which is
associated with increased angiogenesis in the synovium
[15]. Synovitis is also characteristic of rheumatoid arthritis
(RA). Studies of angiogenesis that have compared the
pathogenesis of RA and OA have concluded that angiogen-
esis correlates with the extent of synovial hyperplasia ob-
served in these two diseases and that hyperplasia is most
severe in RA but is also present in OA-affected joints
[16,17]. Angiogenesis also results in innervation of the ar-
ticular cartilage [18], which may provide a source of pain
in OA patients. Thus, an angiogenesis inhibitor that could
suppress synovitis, osteophyte formation, and pain is an at-
tractive candidate for the treatment of OA.
Although an anti-VEGF antibody is an attractive target
for the treatment of neovascular disease, several complica-
tions associated with its intravenous administration have
been reported, including haemorrhage, thromboembolism,
proteinuria, delayed wound healing, and hypertension [19].
In a recent study, we showed that the systemic intravenous
administration of bevacizumab improved articular cartilage
repair in an osteochondral defect model [11]. In the
current study, we first determined how normal joint tissue
responds to bevacizumab treatment. We then evaluated
the effects of intravenous injection of bevacizumab in a
rabbit model of OA by comparing the restorative changes
in the cartilage of the synovium, subchondral bone, and ar-
ticular joint in bevacizumab-treated and untreated rabbits.
Following this, we compared the effects on healing induced
by intra-articular administration with those induced by
intravenous administration of bevacizumab (Figure 1).
Methods
Animals and surgical procedures
Animal experiments were approved by the ethics review
board of Tokai University and were performed inaccordance with the guidelines on animal use of Tokai
University (Authorization Number 122083). Adolescent
Japanese white rabbits, aged 16 to 18 weeks and weigh-
ing about 2.5 kg, were used in this study. These rabbits
were purchased from a professional breeder (Tokyo Jiken
Dobutsu, Tokyo, Japan). The rabbits were anaesthetized
by exposure to sevoflurane and O2 gas. Under sterile con-
ditions, a medial parapatellar approach was used to release
the joint capsule and to perform an anterior cruciate liga-
ment transection (ACLT) [20]. After recovery from sur-
gery, all animals were allowed to walk freely in their cages
without any splints. Animals were sacrificed after the ex-
periments by an overdose of intravenous anaesthesia.
Bevacizumab dose
Intravenous (systemic) administration of bevacizumab
The half-life of bevacizumab in the normal blood circu-
lation is reportedly 21.3 days [21]. In humans, the ap-
proved dose of bevacizumab is 5 mg/kg, with a clinical
administration interval of more than 2 weeks [19]. Beva-
cizumab is cross-reactive with rabbit VEGF, but its affin-
ity for rabbit VEGF is one-eighth that for human VEGF
[22]. Therefore, we investigated bevacizumab at a dose of
40 mg/kg administered on day 1 and again 2 weeks later.
Intra-articular (local) administration of bevacizumab
The local administration of bevacizumab is currently
performed in ophthalmology clinics, in which the drug
is injected into the vitreous body at a concentration of
25 mg/ml [23]. Intravitreal bevacizumab has been shown
to be non-toxic to the retina and optic nerve at the
2.5 mg dose tested in animals [24]. We thus chose to ad-
minister 25 mg/ml into the articular capsule of OA rab-
bits. A volume of 1 ml was deemed suitable because this
is typical for intra-articular injections in rabbits [25].
Experimental design
Experiment 1: normal versus normal bevacizumab
Twelve rabbits were used to investigate the effects of
bevacizumab treatment on normal articular cartilage,
synovium, and subchondral bone. Six rabbits were given
100 mg of bevacizumab intravenously on day 1 and then
again 2 weeks later (normal bevacizumab group, n = 12
knees), and the other six rabbits were used as normal
controls (normal group, n = 12 knees). All rabbits were
sacrificed after 3 weeks to examine gene expression
(normal bevacizumab group, n = 6 knees; normal group,
n = 6 knees) and histology (normal bevacizumab group,
n = 6 knees; normal group, n = 6 knees).
Experiment 2: OA versus OA intravenous bevacizumab
Twenty rabbits underwent bilateral ACLT. Ten rabbits
were given an intravenous injection of 100 mg bevacizu-
mab 1 week and 3 weeks after ACLT (OAB IV group).
Figure 1 Study outline. This study comprised three experiments to assess the effects of bevacizumab in normal and rabbits with osteoarthritis
(OA). Experiment 1: effects of bevacizumab treatment on normal articular cartilage, synovium, and subchondral bone were examined in 12
rabbits. Six normal (untreated) rabbits were given bevacizumab intravenously (iv) on day 1 and at 2 weeks (normal bevacizumab group, n = 12
knees), and the other six normal (untreated) rabbits were used as normal controls (normal group, n = 12 knees). All 12 rabbits were evaluated
after 3 weeks to examine gene expression (normal bevacizumab group, n = 6 knees; normal group, n = 6 knees) and histology (normal
bevacizumab group, n = 6 knees; normal group, n = 6 knees). Experiment 2: 20 rabbits were given bilateral anterior cruciate ligament transection
(ACLT): 10 rabbits were given bevacizumab intravenously 1 week and 3 weeks after ACLT (OAB IV group), and 10 rabbits served as untreated OA
controls (OA group). Rabbits were evaluated 4 weeks (n = 6 rabbits/group) and 12 weeks (n = 4 rabbits/group) after ACLT. Experiment 3: all
rabbits were given unilateral knee ACLT. Intra-articular bevacizumab (25 mg) was injected 4 weeks after ACLT, then weekly until 7 weeks (OAB IA
group). Intravenous bevacizumab (100 mg) was injected 4 and 6 weeks after ACLT (OAB IV group). Rabbits were evaluated 4, 6, and 12 weeks after
ACLT. As the comparison, untreated unilateral ACLT rabbits were examined at the same times (OA group).
Nagai et al. Arthritis Research & Therapy 2014, 16:427 Page 3 of 12
http://arthritis-research.com/content/16/5/427The other 10 rabbits were used as the untreated control
group (OA group). It has been reported that, in unilat-
eral and bilateral ACLT models, degenerative changes
appear in the articular cartilage 4 weeks after surgery
[26-28]. At 4 weeks, six rabbits from each group were
sacrificed for histology (n = 8 knees) and gene expression
(n = 4 knees). The remaining four rabbits in each group
were sacrificed 12 weeks after ACLT, and their tissues
were processed for histology (n = 8 knees).
Experiment 3: OA versus OA intravenous bevacizumab
versus OA intra-articular bevacizumab
The final experiment was designed to compare intraven-
ous with intra-articular administration of bevacizumab.
In this experiment, ACLT was performed on 18 rabbits
on only one knee per rabbit to measure pain behaviour
in terms of weight-bearing asymmetry. Because ACLT
was performed unilaterally in experiment 3, the progress
of OA was predicted to be slower than that in theexperiment involving bilateral ACLT. Therefore, we chan-
ged the timing of the administration of bevacizumab to
4 weeks after ACLT instead of 1 week. Six rabbits were
given 100 mg of bevacizumab by intravenous injection 4
and 6 weeks after ACLT (OAB IV group, n = 6 knees, total
dosage 200 mg), and six rabbits were given 25 mg bevaci-
zumab by intra-articular injection 4, 5, 6, and 7 weeks after
ACLT (OAB IA group, n = 6 knees, total dosage 100 mg).
Six rabbits received no drug treatment (OA group, n = 6
knees). All animals were sacrificed 12 weeks after ACLT,
and the knee joints were evaluated.
Morphology of osteophyte formation
The femoral condyles were examined macroscopically.
Morphological changes were evaluated by two inde-
pendent observers. The criteria for macroscopic grading
were as follows: grade 0 (absent), grade 1 (mild osteo-
phyte formation), grade 2 (moderate osteophyte forma-
tion), and grade 3 (severe osteophyte formation), as
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and chondro-osteophytes in our evaluation of osteophyte
formation because both are regarded as neoplastic tissue
caused by endochondral ossification as a result of angio-
genesis in the articular margin associated with OA. The
formation of chondro-osteophytes by hypertrophic chon-
drocytes reflects the process of endochondral ossification
in the growth of osteophytes. The condyles were prepared
for histological evaluation and gene expression analysis
after morphological grading.
Histological examination
The distal parts of the femur were excised and fixed in
4% paraformaldehyde for 7 days. Each specimen was
decalcified in a solution of 10% ethylenediaminetetraace-
tic acid in distilled water (pH 7.4) for 2 to 3 weeks, em-
bedded in paraffin wax, and cut along the sagittal plane.
Each section was stained with Safranin O. We evaluated
OA repair sites at the medial femoral condyle semiquan-
titatively using a grading and staging system (Osteoarth-
ritis Research Society International (OARSI) modified
Mankin score [30]). This system includes six histological
grades and four histological stages. The total score (grade
score multiplied by stage score) ranges from 1 point (nor-
mal articular cartilage) to 24 points (no repair). The sec-
tions were examined blindly by two observers, and the
scores were averaged to minimize observer bias. The
synovium was sampled from the infrapatellar fat pad
region. The synovial membrane was fixed in 4% parafor-
maldehyde for 7 days and subsequently embedded in
paraffin. Each section was stained with H&E or Masson
trichrome stain.
Gene analysis by real-time polymerase chain reaction (PCR)
The synovium was obtained from the infrapatellar fat
pad region, articular cartilage was sampled from the fem-
oral condyle, and subchondral bone was obtained from
the femoral condyle with completely removed cartilage.
Each construct was homogenized using a Cryo-Press
(Microtec Nition, Chiba, Japan) in liquid nitrogen. Total
RNA was isolated using the SV Total RNA Isolation Sys-
tem (Promega Corp., Madison, WI, USA), following the
manufacturer’s instructions. RNA quantification and qual-
ity were determined using the 260/280 nm ratio. Each
RNA sample was then reverse-transcribed to cDNA using
TaqMan Reverse Transcription reagents (Applied Biosys-
tems, Foster City, CA, USA) in a thermocycler set at 42°C
for 60 minutes and at 95°C for 5 minutes. The primer se-
quences used in this study are listed in Additional file 1:
Table S1. Real-time PCR was performed in an ABI SDS
7300 real-time PCR system (Applied Biosystems) using
SYBR Green Master Mix (Applied Biosystems). cDNA
(2 μl) was added to bring the final volume of the real-time
PCR sample to 25 μl. We then ran 35 to 45 amplificationcycles: 2 minutes at 50°C, 10 minutes at 95°C, 15 s at
95°C, 1 minute at 60°C, and then 15 s at 95°C, 30 s at
60°C, and 15 s at 95°C (dissociation step). Normal
articular cartilage, synovium, or subchondral bone was
used as the reference for comparisons of gene expres-
sion between samples in experiments 1 and 2. The rela-
tive expression of the target mRNA was standardized
to glyceraldehyde phosphate dehydrogenase, and the
expression level was calculated using the 2−ΔΔCT values.
Pain evaluation
An incapacitance test meter (Linton Instrumentation,
Norfolk, England) was used to identify and compare
trends in the weight distribution ratio of the undamaged
versus damaged limbs. The measurements were obtained
from rabbits after they were transferred into the rabbit
holder. The weight distribution of both hind legs was
measured 10 times, and the following formula was used
to calculate the damaged limb weight distribution ratios
(%) obtained by loading the left and right limbs:
Damaged limb weight distribution ratio %ð Þ ¼
fDamaged limb load gð Þ = ðUndamaged limb load
gð Þ þ Damaged limb load gð ÞÞg  100:
Statistical analysis
All data are expressed as the mean ± SD. The nonpara-
metric Mann-Whitney U-test was used to compare gene
expression, histology, and gross morphology between
two groups (experiments 1 and 2). The Kruskal-Wallis
test followed by post hoc comparisons (Mann-Whitney
U-test) was used to compare the pain evaluation test re-
sults and histological data between three groups (experi-
ment 3). Differences were considered significant when
P-values were <0.05 for comparisons between two groups
or <0.017 for comparisons between three groups.
Results
Experiment 1: Effect of bevacizumab in normal tissues
Acute joint damage that occurs at the time of an injury
initiates a sequence of events that can lead to progres-
sive articular surface damage. Therefore, we sought to
compare the gene expression and histological changes in
the synovium, subchondral bone, and articular cartilage
of knees between normal untreated (normal group) and
bevacizumab-treated normal rabbits (normal bevacizu-
mab group) (Figure 2). We administered bevacizumab
intravenously and examined changes in the gene expres-
sion levels of various catabolic factors, including matrix
metalloproteinase-3 (MMP3), MMP13, ADAMTS5 (a
disintegrin and metalloproteinase with thrombospondin
motifs-5), and interleukin-1β (IL-1β). In the synovium,
Figure 2 Comparison of gene expression and histology between the normal bevacizumab and normal groups (experiment 1).
(A) Synovial gene expression. (B) Subchondral bone gene expression. (C) Articular cartilage gene expression. Gene expression data are expressed
as mean ± SD (n = 6 knees). The y-axis is defined as follows: 2–ΔCT normal B target gene/2–ΔCT normal target gene. *P <0.05 by the Mann-Whitney
U-test. (D) Representative articular cartilage histology for the normal group (left side) and normal bevacizumab group (right side) stained with
Safranin O. (E) Representative synovial histology for the normal group (left side) and normal bevacizumab group (right side) stained with H&E.
(F) Higher magnifications of the image in (E) stained with H&E. Histology data were obtained from six knees per group. Bars = 1 mm (E);
bars = 300 μm (D, F).
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normal bevacizumab group compared with the normal
group; MMP3 and Runx2 expression levels were signifi-
cantly lower in the normal bevacizumab group (Figure 2A).
In subchondral bone, IL1B and Runx2 expression levels
were significantly lower in the normal bevacizumab group
than in the normal group (Figure 2B). In articular cartilage,
the expression levels of MMP3, MMP13, and ADAMTS5
were significantly lower in the normal bevacizumab
group compared with the normal group (Figure 2C). In
the articular cartilage, the expression level of collagen
type 2, the major collagen in cartilage, was elevated, but
that of collagen type 1, the major collagen in bone and
tendon, was lower in the normal bevacizumab group
compared with the normal group. The expression levelsof chondromodulin-1 (ChM-1), an endogenous anti-
angiogenic factor, and aggrecan, the major structural
protein in cartilage, were also lower in the normal bevacizu-
mab group compared with the normal group. Intriguingly,
VEGF mRNA expression was unaffected by intravenous ad-
ministration of bevacizumab (Figure 2A-C).
Joints from the normal bevacizumab group showed
smooth and uniform articular surfaces and Safranin O
staining throughout the articular cartilage, similar to the
appearance in the normal group (Figure 2D). In the
synovium in the normal bevacizumab group, there
was no synoviocyte hyperplasia or proliferation, or
lymphoplasmacytic infiltration. One layer of synovial
membrane with underlying adipose cells was apparent
(Figure 2E, F).
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intravenous bevacizumab
We next studied the effects of bevacizumab in a rabbit
model of OA, in which OA was induced by ACLT. Beva-
cizumab was administered 1 and 3 weeks after induction
of OA into 10 rabbits (OAB IV group); 10 untreated OA-
only rabbits served as controls (OA group). All rabbits
were assessed for morphological differences and histo-
logical changes at 4 and 12 weeks, and gene expression
changes were assessed at 4 weeks.
Morphology of osteophyte formation
Four weeks after ACLT, macroscopic evaluation of joints
from both groups identified osteophyte formation but
nearly completely smooth joint surfaces of the articular
cartilage (Figure 3A). The osteophyte formation scoreFigure 3 Comparison of macroscopic and histological evaluations bet
bevacizumab in OA (OAB IV) rabbits (experiment 2). (A) Macroscopic a
transection (ACLT). (B) Macroscopic appearance 12 weeks after ACLT. Circle
and 12 weeks after ACLT. Data are expressed as mean ± SD (n = 8 knees). S
(E) after ACLT. (F) Osteoarthritis Research Society International histological
4 weeks after ACLT. (H) Representative synovial histology for OA group (lef
magnifications of the image shown in (H) stained with HE (I) and Masson
by the Mann-Whitney U-test. Bars = 1 mm (D, E, H); bars = 300 μm (I, J).did not differ between the OA group and the OAB IV
group (Figure 3C). Twelve weeks after ACLT, the joint
surfaces showed a marked progression of arthritis and
osteophyte formation in the OA group. The joints from
the OAB IV group retained smooth joint surfaces in most
regions of the articular cartilage and had significantly less
osteophyte formation (Figure 3B, C).
Histological evaluation of the articular cartilage
We evaluated the medial femoral condyle at the femoral-
tibial (FT) site in the articular cartilage area. Four weeks
after ACLT, histological assessment showed a loss of
Safranin O-positive staining in the OA group, whereas
staining was retained in the OAB IV group (Figure 3D).
By 12 weeks after ACLT, the joints in the OA group
showed delamination of the superficial layer, erosion ofween the osteoarthritis (OA) and intravenous administration of
rticular cartilage appearance 4 weeks after anterior cruciate ligament
s indicate osteophyte formation. (C) Osteophyte formation scores 4
afranin O staining of hyaline cartilage 4 weeks (D) and 12 weeks
score 4 and 12 weeks after ACLT. (G) Macroscopic synovia appearance
t side) and OAB IV group (right side) stained with H&E. Higher
trichrome (J). Data are expressed as mean ± SD (n = 8 knees). *P <0.05
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from the OAB IV group showed smooth and uniform ar-
ticular surfaces and Safranin O staining throughout the ar-
ticular cartilage (Figure 3E). The total OARSI histological
score did not differ between the OA and OAB IV groups
at 4 weeks but was significantly lower in the OAB IV
group than in the OA group at 12 weeks (Figure 3F).
Morphology and histology of the synovium
Four weeks after ACLT, the macroscopic appearance
of the synovium showed enlargement with redness and
recognized thick vascular invasion in the OA group. By
contrast, in the OAB IV group, the synovium was pre-
served and appeared pale yellow, although a thin vascu-
lar invasion was apparent (Figure 3G). Synovial sections
from the OA group showed severe synoviocyte hyper-
plasia with diffuse lymphoplasmacytic infiltration, blood
vessel proliferation, and severe fibroblast proliferation
with regression of adipose cells. These characteristics
were present in the OAB IV group, but they were moreFigure 4 Comparison of relative gene expression levels between the
bevacizumab in OA (OAB IV) groups (experiment 2). (A) Synovial gene
cartilage gene expression. The y-axis is defined as follows: 2–ΔCT OA or OAB
represented as 1 on the y-axis. Data are expressed as mean ± SD (n = 4 knemoderate (Figure 3H, I, J). These results indicate that
the structural damage was less severe in the OAB IV
group than in the OA group.
Gene expression
We harvested the synovium, subchondral bone, and articu-
lar cartilage from the OA and the OAB IV groups 4 weeks
after ACLT. We used real time PCR to assess changes in
the expression of genes involved in anabolic and catabolic
factors, and we compared these changes between the OA
and OAB IV groups relative to the expression levels of the
normal tissues at the baseline. MMP13 gene expression in
the normal synovium was about 10-fold higher in the OA
group than in untreated animals. MMP13 gene expression
in the OAB IV group was one-tenth that in the OA group,
a level that approximated the normal level. ADAMTS5 gene
expression did not increase in the OA group compared
with the normal tissue but was significantly decreased by
administration of bevacizumab (Figure 4A). The effect of
bevacizumab on the OA synovial tissue differed from thatosteoarthritis (OA) and intravenous administration of
expression. (B) Subchondral bone gene expression. (C) Articular
IV target gene/2–ΔCT normal target gene. The normal tissue is
es). *P <0.05 by the Mann-Whitney U-test.
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Runx2 expression was also significantly lower in the OAB
IV group compared with the OA group (Figure 4B). How-
ever, bevacizumab had a similar inhibitory effect on Runx2
expression as in normal subchondral bone (Figure 2B).
Articular cartilage from the OAB IV group showed sig-
nificantly 3.5-fold higher collagen type 2 gene expression
compared with the OA group, and there was a tendency
toward lower collagen type 1 gene expression in the
OAB IV group compared with the OA group (Figure 4C).
The patterns of changes in the expression of types 1 and
2 collagen genes were similar to those induced by bevaci-
zumab treatment in normal articular cartilage (Figure 2C).
Unlike the effect of bevacizumab in normal tissue, aggre-
can and ChM-1 gene expression levels were significantly
higher in the OAB IV group compared with the OA
group. By contrast, MMP13 and ADAMTS5 gene expres-
sion levels were about 2.0-fold higher and VEGF gene
expression level 1.4-fold higher in the OAB IV group than
in the OA group, but this increase was not significant.
MMP3 gene expression levels did not differ between the
OAB IV group and the OA group.
Experiment 3: differences between intravenous and
intra-articular administration of bevacizumab in a
model of OA
Damaged limb weight distribution ratio (%)
A comparison of the weight distribution ratio between
the three groups (OA, OAB IV, and OAB IA) following
bevacizumab treatment is shown in Figure 5A. Up to
6 weeks, the rabbit weight distribution ratio did not differ
between the three groups. However, by 12 weeks, rabbits
in the OAB IA group showed a satisfactory improvement
in the damaged limb weight distribution ratio, whereas
rabbits in the OA and OAB IV groups failed to show such
improvement. The OAB IA group showed significant im-
provement compared with the OA group (Figure 5A). Un-
fortunately, one rabbit from the OAB IV group developed
diarrhoea and lost weight, and this rabbit died from com-
plications involving digestion at 8 weeks.
Histological evaluation
Because unilateral ACLT was performed, the OA change
was not as progressive at the FT site compared with that
observed in rabbits that had received the bilateral ACLT
in experiment 2. Therefore, we divided the distal portion
of the femur into the FT site, femoral-patellar (FP) site,
and corner site, which was between FP and FT (Figure 5B).
In the OA group, diminished Safranin O staining and
clear degeneration of the cartilage were observed at the
FT site. Only minimal Safranin O staining was observed at
the corner and FP sites (Figure 5C). By contrast, in the
OAB IV group, matrix staining was strong at the FT site
throughout the thickness of the cartilage and was strongerat the corner and FP sites compared with the OA group.
Some matrix staining depletion was observed within the
upper third of the cartilage at the corner site and within
the full thickness of the cartilage within the FP site
(Figure 5D). In the OAB IA group, matrix staining de-
pletion was minimal at all three sites, and staining was
observed throughout the full thickness of the tissue
(Figure 5E). As expected, the OARSI histological score
for Safranin O staining at the FT site did not differ signifi-
cantly between the three groups (Figure 5F). However, at
the corner and FP sites, the histological score was signifi-
cantly lower in the OAB IA group than in the OA group
(Figure 5G, H). These results indicate that the OAB IA
group had less OA progression compared with the OAB
IV and OA groups.
Discussion
We previously demonstrated that the intravenous ad-
ministration of bevacizumab repaired articular cartilage
in an osteochondral defect model [11]. Based on those
results, the present study was designed as three separate
experiments to (1) assess the effect of bevacizumab in
normal joints; (2) clarify the therapeutic efficacy of the
intravenous administration of bevacizumab in OA joints;
and (3) evaluate the effects of a systemic versus local ad-
ministration of bevacizumab in OA joints.
The intravenous administration of 100 mg of bevacizu-
mab for a period of 2 weeks did not lead to inflammation
or angiogenic effects in the three tissue types in the
normal joint as determined by histological and gene ex-
pression in experiment 1. The expression of the genes for
some anabolic and catabolic factors was suppressed by ad-
ministration of bevacizumab in normal articular cartilage.
This environment may be the extremely stable hypo-
metabolism, rather than the toxicity to cartilage with
bevacizumab.
Anderson et al. recently reported that early molecular
interventions can limit cartilage degradation by minimiz-
ing the extent of tissue damage and can help accelerate
healing by decreasing the inflammatory response [31]. In
the current study, early intervention by intravenous ad-
ministration of bevacizumab appeared to contribute to a
reduction in articular cartilage degeneration, osteophyte
formation, and synovitis, as determined macroscopically
and histologically in experiment 2.
We performed PCR analyses to assess whether bevaci-
zumab has preventive effects on the whole joint (that is,
by comparing the results of experiments 1 and 2). In the
synovium, MMP13 and ADAMTS5 expression levels were
significantly lower in the OAB IV group than in the OA
group. Although bevacizumab did not decrease IL1B
expression significantly, we suggest that the decrease in
MMP13 and ADAMTS5 expression levels contributed to
the absence of synovitis.
Figure 5 Comparison of pain and histological evaluations between osteoarthritis (OA), intravenous administration of bevacizumab in
OA (OAB IV), and intra-articular administration of bevacizumab in OA (OAB IA) groups (experiment 3). (A) An incapacitance test meter
was used to investigate the pain-ameliorating effects of treatment. The damaged limb weight distribution ratio (%) = {Damaged limb load
(g)/(Undamaged limb load (g) + Damaged limb load (g))} × 100. The damaged limb weight distribution ratios 4, 6, and 12 weeks after surgery
are shown. Data are expressed as mean ± SD (4 and 6 weeks after surgery: for each group, n = 6 knees; 12 weeks after surgery: OA and OAB
IA groups, n = 6 knees, OAB IV group, n = 5 knees). *P <0.05 (Kruskal-Wallis post hoc test and Mann-Whitney U-test). (B) Distribution of
femoral-patellar (FP), corner, and femoral-tibial (FT) sites. Safranin O-stained sections of articular cartilage. Bar = 1 mm. Representative Safranin-
O-stained sections for the (C) OA, (D) OAB IV, and (E) OAB IA groups. Top row, overview of the distal femur. Bar = 1 mm. Second, third, and
fourth rows, enlarged images of the FT site, corner site, and FP site. Bar = 250 μm. Osteoarthritis Research Society International histological scoring
was performed at the (F) FT, (G) corner, and (H) FP sites. Data are mean ± SD (OA and OAB IA groups: n = 6 knees; OAB IV group: n = 5 knees).
*P <0.05 (Kruskal-Wallis post hoc test and Mann-Whitney U-test).
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ported in the synovial tissue of patients with inflamma-
tory joint disease who required synovectomy compared
with healthy control subjects [32]. Acute joint damage
that occurs at the time of an injury initiates a sequence
of events that can lead to progressive articular surface
damage [31]. Subsequently, fragments of cartilage can
induce synovitis in these patients [33]. In this study, dam-
age to the articular surface led to an elevation in VEGF ex-
pression in the articular cartilage. In the synovium, there
was a strong increase in the expression of MMP and IL1B,
which indicates inflammation, but VEGF expression, which
represents angiogenesis, was unchanged. This is probablybecause our study examined the early stages of OA
(4 weeks after ACLT). Therefore, it seems likely that VEGF
expression in the synovial tissue was not influenced by bev-
acizumab treatment.
Runx2 is the master gene of bone formation and con-
tributes to sclerosis in subchondral bone and the forma-
tion of osteophytes [34]. From the early stages in our
model, we observed a significant decrease in Runx2 ex-
pression with bevacizumab treatment, suggesting that bev-
acizumab contributes to the inhibition of osteosclerosis in
the subchondral bone and inhibits osteophyte formation.
In this study, the expression of both VEGF and ChM-1
was examined in the articular cartilage. We consider that
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http://arthritis-research.com/content/16/5/427the balance between angiogenic and anti-angiogenic fac-
tors is important to articular chondrocyte survival and
preservation of the phenotype. The expression of ChM-
1, which was lower in the OA group than in the normal
group, increased with bevacizumab treatment. ChM-1 is
reported to be a strong inhibitor of angiogenesis involved
in the development of bone and regulation of vascular in-
vasion during endochondral bone formation [35]. Articu-
lar cartilage contains considerable amounts of ChM-1,
which should induce the chondrocyte phenotype [36]. It
has been posited that the development of the OA pheno-
type might result from articular chondrocytes undergoing
a differentiation route reminiscent of growth plate chon-
drocytes and expressing hypertrophy-like changes [37].
Thus, ChM-1 may act to prevent chondrocyte hyper-
trophy and to stabilize the articular chondrocyte pheno-
type [38].
VEGF is necessary for chondrocyte survival during
cartilage development [39]. In an osteochondral defect
model, we showed previously that administration of
bevacizumab caused ChM-1 to accumulate in the inter-
territorial space of the repaired matrix surrounding the
chondrocytes, which expressed VEGF [11]. In the articu-
lar cartilage, although VEGF expression was 2.4-fold
higher in the OA group than in normal tissue from un-
treated rabbits, bevacizumab did not significantly alter
VEGF expression.
The gene expression levels of the anabolic factors
aggrecan and collagen type 2 were significantly higher in
the OAB IV group than in the OA group. Interestingly,
the gene expression of the catabolic factors in the articu-
lar cartilage, MMP13 and ADAMTS5, were higher in
the OAB IV group than in the OA group, although this
difference was not significant. Because this study was
performed in vivo, we consider that the expression of
the catabolic genes may have led to degradation of the
existing matrix and subsequent proliferation and synthe-
sis of new matrix in the limited articular cartilage space.
The increase in ChM-1 expression in response to bevaci-
zumab may have increased the anabolic and catabolic fac-
tors, leading to proliferation and synthesis of new matrix
in vivo. Interestingly, however, in normal articular cartil-
age, ChM-1 expression was decreased by administration
of bevacizumab (Figure 2C). Kitahara et al. suggested that
ChM-1 acts to inhibit vascular invasion in the immature
state of articular cartilage and that ChM-1 levels decrease
gradually with age thereafter [40]. Such findings suggest a
regulatory role of ChM-1 in vascular invasion; that is,
exposure of tissues to angiogenesis factors is reduced in
mature articular cartilage concomitant with a reduction in
ChM-1 at both the protein and gene expression levels. In
other words, ChM-1 appears to decrease at the non-
angiogenic sites. In the current study, it is possible that
angiogenic factors were reduced at the protein level afterbevacizumab administration in the normal articular cartil-
age; if so, ChM-1 gene expression would have also de-
creased following the administration of bevacizumab in
normal articular cartilage.
One limitation of this study is that we did not measure
VEGF protein levels in the tissue before and after
treatment with bevacizumab, which is important when
examining the treatment effects of bevacizumab. In this
experiment, intermittent treatment with bevacizumab in-
duced less OA progression, as shown by both histological
and gene expression assays, through increases in the gene
expression of ChM-1 and VEGF in the articular cartilage
and decreases in the gene expression of MMP 13 and
ADAMTS5 in the synovium. Thus, although bevacizumab
bound to VEGF protein, this did not prevent the expres-
sion of VEGF, which is needed for cartilage survival. In
addition, it is thought that bevacizumab functions to
modify the local environment by preventing angiogenesis
in articular cartilage and synovial inflammation. Further
research is required to understand better what determines
the magnitude of the increase in ChM-1 at both the pro-
tein and gene expression levels in response to bevacizu-
mab in OA tissues. It is important to understand the
pharmacokinetic profile of the drug if we are to optimize
dosing regimens for patients and to obtain a better assess-
ment of its safety profile.
The second limitation of this study is that we did not
monitor the dose-response relationship for bevacizumab
because a sufficient preventive effect against OA pro-
gression occurred with the intravenous administration of
200 mg (2 × 100 mg) of bevacizumab and intra-articular
administration of 100 mg (4 × 25 mg) of bevacizumab.
In the absence of intravenous administration of bevaci-
zumab, intra-articular administration may lead to beva-
cizumab being absorbed by the highly vascular synovial
membrane and then circulated throughout the whole
body. Therefore, some of the effects of the intra-articular
injection of bevacizumab may be attributable to its pres-
ence in the systemic circulation. Future studies should as-
sess the effects of tapered dosages of bevacizumab and the
optimal systemic dosage.
We have shown here that intravenous administration
of bevacizumab is associated with reductions in syno-
vitis, articular degeneration, and osteophyte formation in
an ACLT model of OA. Systemic bevacizumab-treated
joints also generally showed greater aggrecan preserva-
tion, as indicated by the intensity of Safranin O staining
of the articular cartilage (Figure 3). These results are
promising for translating this study into the clinical set-
ting. As described earlier, there are numerous potential
side effects of systemic administration of bevacizumab.
It is likely that the intra-articular administration of beva-
cizumab will decrease the risk of these adverse events.
In this study, there was no disadvantage associated with
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with intravenous administration. The total dose of the
drug given to the OAB IA group was half that given to
the OAB IV group. Moreover, the animals exhibited
significantly less pain in the OAB IA group. Bonnet and
Walsh commented that angiogenesis may introduce sen-
sory nerves into the aneural cartilage and that inflamma-
tion can sensitize nerves present in the joint [33]. It is
believed that the intra-articular administration of bevaci-
zumab inhibits angiogenesis and inflammation, thereby
reducing OA progression and providing pain relief. Be-
cause ACLT was performed unilaterally in experiment 3,
the progression of OA was slower than that in experiment
2, which involved bilateral ACLT. Similar to experiment 2,
the differences in the histological score and pain behav-
iour between the OA and OAB IV groups in experiment 3
will seem to occur after 12 weeks. Intravenous administra-
tion of bevacizumab is a promising treatment option for
polyarthritis, whereas intra-articular administration might
be recommended for patients with single-site arthritis.
Conclusions
In conclusion, we show that bevacizumab reduced syno-
vitis, osteophyte formation, and cartilage degradation in
a rabbit model of OA. Importantly, intra-articular ad-
ministration of bevacizumab also reduced pain behav-
iour. Because bevacizumab was administered before the
development of structurally severe OA, its effects might
reflect changes in synovitis rather than direct effects on
cartilage pathogenesis. Our findings indicate that early
intervention by the administration of bevacizumab fol-
lowing an ACL injury may be beneficial in retarding the
development of post-traumatic OA.
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